Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GW493838 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| GW493838 | DRUG | - |
Inclusion criteria (subjects must meet all of the following criteria in order to be eligible for this study): * Females of non-child-bearing potential * diagnosis of peripheral neuropathic pain as a result of: postherpetic neuralgia (PHN) from shingles for at least 3 months duration OR focal neurop...
Top 3 of 4 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 1 | PHASE2 | LY3016859, LY3556050, LY3526318, LY3857210, LY4065967 ISA |
| Dogwood Therapeutics Inc | DWTX | 1 | PHASE2 | Halneuron |
| Sangamo Therapeutics, Inc. | SGMO | 1 | PHASE1 | ST-503 |
GW493838 was developed for the treatment of neuropathic pain, specifically peripheral neuropathic pain. It is a small molecule therapeutic candidate studied in adult patients aged 18 years and older. The clinical program focused on pain as its therapeutic area, and the compound has been evaluated in a Phase 2 study.
GW493838 targets the adenosine A1 receptor, also known as ADORA1. It acts as an agonist at this receptor, meaning it activates the receptor rather than blocking it. This mechanism was the basis for its investigation in peripheral neuropathic pain, where adenosine A1 receptor activation is thought to play a role in pain signaling.
GW493838 was developed by GSK plc, which trades under the ticker GSK. The compound, a small molecule adenosine A1 receptor agonist, was advanced into clinical testing by the company as part of its pain research efforts.
GW493838 is in Phase 2 development. It has been evaluated in a completed Phase 2 clinical trial in patients with peripheral neuropathic pain. The drug is investigational and has not been approved for any indication.
GW493838 has been studied in one clinical trial, NCT00376454, titled "The Study of GW493838, an Adenosine A1 Agonist, in Peripheral Neuropathic Pain." This completed Phase 2 trial enrolled 113 participants in the United States and was randomized and double-blind, with an uncontrolled design.